-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2212 Neutrophil Infiltration Is Partially Inhibited By EC-18 in the LPS-Induced Acute Lung Injury

Granulocytes, Monocytes and Macrophages
Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes and Macrophages: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Su-Hyun Shin1*, Ha-Reum Lee, Ph.D.1*, Nina Yoo1*, Sun Young Yoon, Ph.D.2*, Myung-Hwan Kim, MD, Ph.D.3*, Cheolwon Suh4, Ki-Young Sohn2*, Heung-Jae Kim, Ph.D.2*, Yong-Hae Han, Ph.D.2*, Saeho Chong, Ph.D.2* and Jae Wha Kim, Ph.D.1*

1Biomedical Translational Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
2Enzychem Lifesciences Corporation, Weehawken, NJ
3Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Acute lung injury (ALI) is an acute respiratory failure and linked closely to neutrophil accumulation. It can lead to acute respiratory distress syndrome (ARDS). Mouse model of ALI was established by lipopolysaccharide (LPS) administration. LPS, an outer membrane of gram negative bacteria, is considered as immune stimulator via recognition as pathogen-associated molecular patterns (PAMP). ALI and neutrophil infiltration were readily induced by intranasal injection of LPS. In this study, we investigated whether EC-18 treatment attenuates LPS-induced ALI. EC-18 (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) is an immune modulator in the allergic asthma response through modulation of the balance between Th1 and Th2. To analyze the role of EC-18 in LPS-induced ALI mice, Balb/c mice were divided into three separate groups: control, LPS treated, and EC-18/LPS co-treated (n=5 per group). 25 mg/kg of LPS was administered by an intranasal route, and 250 mg/kg of EC-18 was orally administered. Mice were sacrificed after 15hrs, and various samples were collected. Bone marrow cells, whole blood cells, cells in lung and bronchoalveolar lavage fluid (BALF) were analyzed using complete blood count (CBC) assay. As results, the number of neutrophil in the bone marrow was decreased in the LPS treated group, and the circulating neutrophil, neutrophil in the lung and BALF were significantly increased in the LPS treated group. Neutrophils in the lung and BALF were dramatically decreased in the EC-18/LPS co-treated group. Also, Evans Blue staining of the lung indicated that capillary permeability was enhanced in the LPS injected mice, and this permeability was lessened in the EC-18/LPS co-treated group as much as that of control. These findings suggested that EC-18 could effectively block neutrophil transmigration into the lung and vesicular leakage. Consequently, EC-18 could be utilized as a potential therapeutic agent for acute and chronic inflammation related disease like ALI.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH